Hepatitis C virus (HCV) causes persistent infection and invades host's innate and adaptive immune systems. During the eradication of this pathogen, the components of immune system may cause bystander damage to host, which might be even worse than the viral pathogenesis. Thus, the therapy should not only eliminate primary virus infection but also improve the inflammatory immune responses. The breakthrough of interferon free direct acting antiviral (DAA) drugs has provided the opportunity to unravel the association of HCV with immune response. This study aimed to examine the expression level of C-X-C motif chemokine ligand 10 (CXCL10) in the Peripheral blood mononuclear cells (PBMCs) of HCV infected patients treated with DAAs + Ribavirin. In this study we analyzed the expression levels of CXCL10 mRNA in the 90 chronic HCV patients using quantitative PCR (qPCR) prior, after, and during therapy with sofosbuvir/ribavirin (SOF+RBV) and sofosbuvir/daclatasvir/ribavirin (SOF+DCV+RBV), and further, the results were analyzed relative to treatment response. Significantly elevated CXCL10 mRNA was seen in naive patients having higher viral load (P = 0.005) and those suffering from hepatocellular carcinoma (P = 0.006). HCV patients had remarkable decline in CXCL10 level after 4, 12, and 24 weeks of therapy with DAAs. An approximate one-fold decrease was observed in patients who attained sustained virological response compared to untreated patients (P < 0.0001). Comparing the 2 regimens, the reduction in peripheral CXCL10 expression was more pronounced in patients undergoing SOF+DCV+RBV therapy. The current study implicitly shows the role of CXCL10 as an indicator of disruption of host-virus equilibrium and consequent pathogenesis of HCV during successful antiviral therapy. Furthermore, the drop in CXCL10 level after HCV viral clearance might reflect the DAA-induced alleviation in the extrahepatic manifestation of this infection.
Get full access to this article
View all access options for this article.
References
1.
AbrahamR, RamakrishnaB, BalekuduruA, DanielHDJ, AbrahamP, EapenCE, KurianG. 2009. Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease. Indian J Gastroenterol, 28(2):53.
2.
AghaS, Al-GendyM, El-FikyA, El-EmshatyW. 1999. Correlation of serum hepatitis C virus RNA titre with aminotransferases and liver histopathological findings in HCV-seropositive cases with end-stage chronic liver disease. Microbes Infect, 1(13):1091–1094.
3.
AskariehG, Alsiö Å, PugnaleP, NegroF, FerrariC, NeumannAU, PawlotskyJM, SchalmSW, ZeuzemS, NorkransG. 2010. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology, 51(5):1523–1530.
4.
AttaullahS, KhanS, AliI. 2011. Hepatitis C virus genotypes in Pakistan: a systemic review. Virol J, 8(1):433.
5.
BaldickCJ, WichroskiMJ, PendriA, WalshAW, FangJ, MazzuccoCE, PokornowskiKA, RoseRE, EggersBJ, HsuM. 2010. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog, 6(9):e1001086.
BeanM, TangL, KottililS, BeaversKL, MeissnerEG. 2016. On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series. Case Rep Infect Dis, 2016:6151570
ButeraD, MarukianS, IwamayeAE, HembradorE, ChambersTJ, Di BisceglieAM, CharlesED, TalalAH, JacobsonIM, RiceCM. 2005. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood, 106(4):1175–1182.
10.
ChatterjeeA, GuedjJ, PerelsonAS. 2012. Mathematical modeling of HCV infection: what can it teach us in the era of direct antiviral agents?. Antivir Ther, 17(6 Pt B):1171–1182.
11.
ChenM-F, TsaiH-P, JengL-B, LeeW-C, YehC-N, YuM-C, HungC-M. 2003. Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: univariate and multivariate analysis. World J Surg, 27(4):443–447.
CotlerS, WartelleC, LarsonA, GretchD, JensenD, CarithersJR. 2000. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat, 7(3):211–217.
14.
DhingraS, WardSC, ThungSN. 2016. Liver pathology of hepatitis C, beyond grading and staging of the disease. World J Gastroenterol, 22(4):1357.
15.
FosterGR, IrvingWL, CheungMC, WalkerAJ, HudsonBE, VermaS, McLauchlanJ, MutimerDJ, BrownA, GelsonWT. 2016. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol, 64(6):1224–1231.
16.
FriedMW, ShiffmanML, ReddyKR, SmithC, MarinosG, GonçalesFL Jr, HäussingerD, DiagoM, CarosiG, DhumeauxD. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 347(13):975–982.
17.
HarveyCE, PostJJ, PalladinettiP, FreemanAJ, FfrenchRA, KumarRK, MarinosG, LloydAR. 2003. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol, 74(3):360–369.
18.
HaybaeckJ, ZellerN, WolfMJ, WagnerU, KurrerMO, BremerJ, WeberA, IezziG, GrafR, ClavienP-A. 2011. A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. In Advances in TNF family research: proceedings of the 12th International TNF Conference, 2009. Springer. pp. 681–681.
19.
HiranoS, IwashitaY, SasakiA, KaiS, OhtaM, KitanoS. 2007. Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes. J Gastroenterol Hepatol, 22(5):690–696.
20.
JacobsonIM, GordonSC, KowdleyKV, YoshidaEM, Rodriguez-TorresM, SulkowskiMS, ShiffmanML, LawitzE, EversonG, BennettM. 2013. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med, 368(20):1867–1877.
21.
LaggingM, RomeroAI, WestinJ, NorkransG, DhillonAP, PawlotskyJM, ZeuzemS, von WagnerM, NegroF, SchalmSW. 2006. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology, 44(6):1617–1625.
22.
LarrubiaJ-R, CalvinoM, BenitoS, Sanz-de-VillalobosE, PernaC, Pérez-HornedoJ, González-MateosF, García-GarzónS, BienvenidoA, ParraT. 2007. The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. J Hepatol, 47(5):632–641.
23.
LawitzE, LalezariJP, HassaneinT, KowdleyKV, PoordadFF, SheikhAM, AfdhalNH, BernsteinDE, DeJesusE, FreilichB. 2013. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis, 13(5):401–408.
24.
LiL, ZhuY, LiY, GuanX-Y. 2017. Identification of chemokine CXCL10 in tumor microenvironment by antibody array as a prognostic marker in hepatocellular carcinoma. Neoplasma, 64(5):778–786.
25.
LiY, ZhuC, WangF, ZhuT, LiJ, LiuS, XiaoF. 2016. Expression of interferon effector gene SART1 correlates with interferon treatment response against hepatitis B infection. Mediators Inflamm, 2016:3894816.
26.
LiangC-M, ChenL, HuH, MaH-Y, GaoL-L, QinJ, ZhongC-P. 2015. Chemokines and their receptors play important roles in the development of hepatocellular carcinoma. World J Hepatol, 7(10):1390.
27.
LinJC, HabersetzerF, Rodriguez-TorresM, AfdhalN, LawitzEJ, PaulsonMS, ZhuY, SubramanianGM, McHutchisonJG, SulkowskiM. 2014. Interferon γ–induced protein10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. J Infect Dis, 210(12):1881–1885.
28.
LinW, KimSS, YeungE, KamegayaY, BlackardJT, KimKA, HoltzmanMJ, ChungRT. 2006. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol, 80(18):9226–9235.
29.
LuM-Y, HuangC-I, HsiehM-Y, HsiehT-J, HsiE, TsaiP-C, TsaiY-S, LinC-C, HsiehM-H, LiangP-C. 2016. Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. Oncotarget, 7(38):61325.
30.
MatsuuraK, WatanabeT, IijimaS, MurakamiS, FujiwaraK, OritoE, IioE, EndoM, KusakabeA, ShinkaiN. 2014. Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C. Hepatol Res, 44(12):1208–1216.
31.
McHutchisonJG, GordonSC, SchiffER, ShiffmanML, LeeWM, RustgiVK, GoodmanZD, LingM-H, CortS, AlbrechtJK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med, 339(21):1485–1492.
32.
MeissnerEG, KohliA, HigginsJ, LeeYJ, ProkuninaO, WuD, OrrC, MasurH, KottililS. 2017. Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. Hepatol Commun, 1(7):586–594.
33.
NelsonDR, CooperJN, LalezariJP, LawitzE, PockrosPJ, GitlinN, FreilichBF, YounesZH, HarlanW, GhalibR. 2015. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology, 61(4):1127–1135.
34.
NishikawaH, EnomotoH, NasuA, AizawaN, SaitoM, TamoriA, KawadaN, KimuraT, OsakiY, NishiguchiS. 2014. Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. Hepatol Res, 44(14):E397–E407.
35.
NkontchouG, ZiolM, AoutM, LhabadieM, BaaziaY, MahmoudiA, RoulotD, Ganne-CarrieN, Grando-LemaireV, TrinchetJC. 2011. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat, 18(10):e516–e522.
36.
OsinusiA, MeissnerEG, LeeY-J, BonD, HeytensL, NelsonA, SnellerM, KohliA, BarrettL, ProschanM. 2013. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA, 310(8):804–811.
37.
ReddyS, SharmaRK, MehrotraS, PrasadN, GuptaA, KaulA, Singh BhadauriaD. 2018. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Clin Kidney J, 11(3):429–433.
38.
ReuterSE, FaullRJ, RanieriE, EvansAM. 2009. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients. Nephrol Dial Transplant, 24(3):990–996.
39.
ScheuerPJ, AshrafzadehP, SherlockS, BrownD, DusheikoGM. 1992. The pathology of hepatitis C. Hepatology, 15(4):567–571.
40.
SchmittgenTD, LivakKJ. 2008. Analyzing real-time PCR data by the comparative C T method. Nat Protoc, 3(6):1101.
41.
ShepherdJ, BrodinH, CaveC, WaughN, PriceA, GabbayJ. 2004. Pegylated interferon α-2a and-2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. In: NIHR Health Technology Assessment programme: Executive Summaries. Scotland: NIHR Journals Library.
42.
SorianoV, YoungB, ReauN. 2018. Report from the international conference on viral hepatitis-2017. AIDS Rev, 20(1):58–70.
43.
SpurrellJC, WiehlerS, ZaheerRS, SandersSP, ProudD. 2005. Human airway epithelial cells produce IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection. Am J Physiol Lung Cell Mol Physiol, 289(1):L85–L95.
44.
TabllAA, KodousMA, AbbasAT, OmranMM, ElsayedEH. 2016. Association between serum aminotransferase enzymes–lipid profile ratio and spontaneous HCV clearance in blood donors. Future Virol, 11(1):19–29.
45.
TannerM, BerkL, FeltenD, BlidyA, BitS, RuffD. 2002. Substantial changes in gene expression level due to the storage temperature and storage duration of human whole blood. Clin Lab Haematol, 24(6):337–341.
46.
TsaiM-H, LinK-H, LinK-T, HungC-M, ChengH-S, TyanY-C, HuangH-W, Sanno-DuandaB, YangM-H, YuanS-S. 2015. Predictors for early identification of hepatitis C virus infection. BioMed Res Int, 2015:429290.
47.
WardJW. 2016. Global elimination of hepatitis C virus. Gastroenterol Hepatol, 12(10):632.
48.
ZeremskiM, DimovaRB, BenjaminS, PenneyMS, BotfieldMC, TalalAH. 2015. Intrahepatic and peripheral CXCL10 expression in hepatitis C virus–infected patients treated with telaprevir, pegylated interferon, and ribavirin. J Infect Dis, 211(11):1795–1799.
49.
ZeremskiM, PetrovicLM, ChiribogaL, BrownQB, YeeHT, KinkhabwalaM, JacobsonIM, DimovaR, MarkatouM, TalalAH. 2008. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology, 48(5):1440–1450.
